Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Arbutus Biopharma, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Spikevax appears in 2 tracked Cross-Sector stories from March 4, 2026.
2 verified stories tracked
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Arbutus Biopharma, the most common co-covered peer. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Spikevax appears in 2 tracked Cross-Sector stories from March 4, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spikevax. Shared-story counts are live from our verified record — not editorial picks.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
Claims Construction
Court rulings on patent definitions provide momentum for the plaintiffs.
Lawsuit Filed
Arbutus and Genevant sue Moderna for patent infringement in Delaware federal court.
Vaccine Launch
Moderna receives EUA for Spikevax, utilizing LNP technology for delivery.
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
